Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk Dives On Rare Miss As Pricing Pressure Weighs On Ozempic, Wegovy
Novo Nordisk stock tumbled Wednesday after the drugmaker reported a rare sales miss for its two biggest moneymakers, Ozempic and Wegovy.
Novo Nordisk Slides as Weight-Loss Drugs Fuel Less Growth Than Expected
Novo Nordisk's (NVO) American depositary receipts (ADRs) slipped in pre-market trading Wednesday morning after rising sales of the company's weight-loss drugs failed to boost earnings to the level of growth analysts expected for the quarter.
Novo Nordisk: Growth Only Limited By Manufacturing Capacity
Novo has helped to create a new market that should provide over 20% growth in the medium term. Three additional drivers for Novo include increasing obesity treatment capacity, insurance coverage, and the development of new pill-based obesity treatments. At 1.5x PEG I arrive at a YE25 price target of US$162 +29% upside potential.
Novo Nordisk (NVO) Falls as Q2 Earnings and Sales Miss, View Up
Novo Nordisk (NVO) falls as it reports lower-than-expected Q2 results, missing both earnings and revenue estimates. However, sales of Diabetes and Obesity care products increase year over year.
US patients staying on Wegovy obesity drug for 'around six months', Novo Nordisk says
U.S. patients are staying on Novo Nordisk's Wegovy weight-loss medication for "around six months", an executive said on Wednesday, adding that the company is confident that over time as shortages ease that will increase to 12 months.
Novo Nordisk's Wegovy miss 'will likely raise questions', says investment bank
Ozempic maker Novo Nordisk's (NYSE:NVO) weightloss drug sales were below expectations in the second quarter but this is not a significant concern, analysts said. Sales of Wegovy, the brand for semaglutide approved as a weightloss treatment, came in 14% below consensus, while sales of Ozempic, which is approved in the US for diabetes, were 3% lower than consensus forecasts.
Is It Too Late to Buy Novo Nordisk Stock After Its 57% Surge?
Novo Nordisk is the leader in the glucagon-like peptide 1 (GLP-1) agonists market with 70% share. The company has notched some big wins with Wegovy this year, opening up several new billion-dollar markets.
Ozempic Maker Novo Nordisk Sinks On Disappointing Earnings Amid Booming Demand For Weight Loss And Diabetes Drugs
Pharma giant Novo Nordisk on Wednesday reported booming demand for its weight loss and diabetes drugs Ozempic and Wegovy, but shares sank after the Danish firm disappointed investors with less-than-expected profits for the second quarter and a slimmed-down profit outlook for the year as it faces growing competition in the lucrative market and pressure to ease persistent supply constraints.
Ozempic maker Novo Nordisk falls after cutting profit outlook
Shares in Novo Nordisk (NYSE:NVO), the maker of weightloss and diabetes drugs Wegovy and Ozempic, fell over 5% after it slightly lowered the profit outlook for this year. Operating profit for Europe's largest company by market valuation increased 18% in the second quarter of 2024 to 57.8 billion Danish krone (DKK), slower than the 27% growth seen in the first quarter.
Ozempic maker Novo Nordisk misses profit estimates as it builds out capacity
Novo Nordisk, Europe's largest company by market cap thanks to its wildly popular weight-loss drugs, managed just a small increase in second-quarter profits as it builds out the capacity to make the products.
Wegovy maker Novo Nordisk posts earnings miss, cuts operating profit outlook
Novo Nordisk on Wednesday announced its second quarter earnings for 2024.
Obesity drugmaker Novo Nordisk misses Q2 profit forecast
Novo Nordisk on Wednesday posted second-quarter operating profit below expectations, raised its 2024 sales forecast but cut profit outlook, as competition from Eli Lilly in the booming weight-loss drug market intensifies.
